Ultragenyx drops on Phase 3 trial failure for Angelman syndrome drug
We haven't written up this one. Seeking Alpha News has the full story — the link below goes straight to it.
More in Finance & Markets
India bonds gain as RBI FX inflows lift liquidity, spur short-term debt buying
MUMBAI: Indian government bonds rose in early trade on Thursday, led by the shorter-duration papers, after larger-than-expected dollar inflows under the central bank’s special schemes boosted rupee…
ICICI Bank narrows gap on HDFC Nifty lead
HDFC Bank is close to losing its position as the heaviest stock in the Nifty 50 to ICICI Bank after a sharp share-price decline narrowed the difference between the two lenders to less than half a…
Prediction: Here's Where Palantir Stock Will Be in 3 Years
Key PointsPalantir's revenue growth continues to accelerate.
BoG Warns Public Against ‘Daily Wealth Guide’ Crypto Scam
The Bank of Ghana (BoG) and the Securities and Exchange Commission (SEC) have warned the public against a fraudulent crypto investment platform known as “Daily Wealth Guide,” which is allegedly…
Lumino Industries shares soar 40% from IPO price after strong market debut. Should you buy or wait?
Lumino Industries shares extended their strong debut gains, rising another 4% after listing at a 34% premium to the IPO price.